rolofylline rolofylline rolofylline (kw-3902) is an experimental diuretic which acts as a selective adenosine a1 receptor antagonist. it was discovered at novacardia, inc. which was purchased by merck & co., inc. in 2007. rolofyllineclinical dataatc codec03bd (who) legal statuslegal status us: ℞-only identifiers iupac name 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-3,7-dihydro-1,3-dipropyl-1h-purine-2,6-dione cas number136199-02-5pubchem cid64627iuphar/bps5604drugbankdb12670chemspider58188unii7805s5hihxkeggd08989chebichebi:177647chemblchembl52333comptox dashboard (epa)dtxsid50929292 echa infocard100.190.068 chemical and physical dataformulac20h28n4o2molar mass356.470 g·mol−13d model (jsmol)interactive image smiles cccn1c(=o)c2c(c34cc5cc(cc(c5)c3)c4)nc2n(ccc)c1=o inchi inchi=1s/c20h28n4o2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14h,3-11h2,1-2h3,(h,21,22)key:pjbfvwgqflywcb-uhfffaoysa-n development of rolofylline was terminated on september 1, 2009, after the results of a large clinical trial (protect) showed the drug to be no better than placebo for patients with acute heart failure. participants given rolofylline did show some improvement in shortness of breath, but the drug did not prevent kidney damage or have any significant effect on overall treatment success. rolofylline was also associated with a higher incidence of seizures and stroke.